IGC Pharma (IGC) Cash & Equivalents (2010 - 2026)

IGC Pharma (IGC) has reported Cash & Equivalents for 17 consecutive years, with $235000.0 the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash & Equivalents fell 41.98% year-over-year to $235000.0; the TTM figure through Mar 2026 stood at $235000.0 (down 41.98% YoY), while the FY2026 annual figure was $235000.0, down 41.98% from the prior year.
• Cash & Equivalents retreated to $235000.0 in Q1 2026 per IGC's latest filing, from $938000.0 in the prior quarter.
• Across five years, Cash & Equivalents topped out at $10.5 million in Q1 2022 and bottomed at $235000.0 in Q1 2026.
• Historically, Cash & Equivalents has averaged $2.8 million across 5 years, with a median of $1.5 million in 2024.
• Annual changes were most pronounced in 2023 — Cash & Equivalents tumbled 78.6% — and 2025, when it surged 99.57%.
• IGC Pharma's Cash & Equivalents stood at $4.9 million in 2022, then plunged by 72.13% to $1.4 million in 2023, then plunged by 65.89% to $470000.0 in 2024, then soared by 99.57% to $938000.0 in 2025, then sank by 74.95% to $235000.0 in 2026.
• Business Quant data shows IGC's Cash & Equivalents at $235000.0 in Q1 2026, $938000.0 in Q4 2025, and $1.1 million in Q3 2025.